Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation
Neuroendocrine differentiation of prostate cancer (NEDPC) includes de novo presentation and secondary to epigenetic changes, referred as therapy-induced neuroendocrine prostate cancer (t-NEPC). Molecular imaging with prostate-specific membrane antigen (PSMA) and somatostatin analogues positron emiss...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/12/6/1387 |
| _version_ | 1797488314902642688 |
|---|---|
| author | Joel Vargas Ahumada Sofía D. González Rueda Fabio A. Sinisterra Solís Quetzali Pitalúa Cortés Liliana P. Torres Agredo Jimenez Ríos Miguel Anna Scavuzzo Irma Soldevilla-Gallardo Miguel A. Álvarez Avitia Nora Sobrevilla Francisco Osvaldo García Pérez |
| author_facet | Joel Vargas Ahumada Sofía D. González Rueda Fabio A. Sinisterra Solís Quetzali Pitalúa Cortés Liliana P. Torres Agredo Jimenez Ríos Miguel Anna Scavuzzo Irma Soldevilla-Gallardo Miguel A. Álvarez Avitia Nora Sobrevilla Francisco Osvaldo García Pérez |
| author_sort | Joel Vargas Ahumada |
| collection | DOAJ |
| description | Neuroendocrine differentiation of prostate cancer (NEDPC) includes de novo presentation and secondary to epigenetic changes, referred as therapy-induced neuroendocrine prostate cancer (t-NEPC). Molecular imaging with prostate-specific membrane antigen (PSMA) and somatostatin analogues positron emission tomography (PET/CT) in NEDPC have not been validated. <sup>18</sup>F-FDG (fluorodeoxyglucose) PET/CT has numerous limitations in prostate cancer (PCa) and the utility in NEDPC has only been reported in a few series of cases. The objective of this study is to compare the lesions detection rate of the three radiotracers in metastatic t-NEPC patients. (1) Material and Methods: Retrospective evaluation of patients with prostate adenocarcinoma treated with androgen deprivation therapy, chemotherapy, a novel androgen receptor pathway inhibitor or a combination of them and a second tumour biopsy confirming t-NEPC was made. All patients underwent <sup>18</sup>F PSMA-1007, <sup>18</sup>F AlF-NOTA-Octreotide, and <sup>18</sup>F-FDG PET/CT. Evaluation of positive lesions was determined and SUVmax of each radiotracer was estimated and correlated with computer tomography (CT) findings. (2) Results: A total of eight patients were included. The mean time from diagnosis of prostate adenocarcinoma to t-NEPC was 28.2 months, with a mean serum specific prostate antigen (PSA) of 16.6 ng/dl at the time of NEPC diagnosis. All patients were treated with antiandrogen therapy and 87.5% with chemotherapy. A total of 273 lesions were identified by CT from which 182 were detected by <sup>18</sup>F-FDG PET/CT, 174 lesions by <sup>18</sup>F PSMA-1007, and 59 by <sup>18</sup>F AlF-NOTA-Octreotide. An interpatient analysis of the lesions was performed and dual tracer <sup>18</sup>F-FDG PET/CT and <sup>18</sup>F PSMA-1007 PET/CT detected a total of 270/273 lesions (98.9%). (3) Conclusions: NEDPC patients demonstrated wide inter and intrapatient molecular imaging heterogeneity within the three radiotracers. <sup>18</sup>F-FDG detected most lesions in t-NEPC among all radiotracers, especially in visceral sites; <sup>18</sup>F PSMA-1007 detected more bone lesions. <sup>18</sup>F AlF-NOTA-Octreotide showed no significant utility. |
| first_indexed | 2024-03-10T00:00:22Z |
| format | Article |
| id | doaj.art-66162221b73742a58ef97a53d7399168 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T00:00:22Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-66162221b73742a58ef97a53d73991682023-11-23T16:17:19ZengMDPI AGDiagnostics2075-44182022-06-01126138710.3390/diagnostics12061387Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine DifferentiationJoel Vargas Ahumada0Sofía D. González Rueda1Fabio A. Sinisterra Solís2Quetzali Pitalúa Cortés3Liliana P. Torres Agredo4Jimenez Ríos Miguel5Anna Scavuzzo6Irma Soldevilla-Gallardo7Miguel A. Álvarez Avitia8Nora Sobrevilla9Francisco Osvaldo García Pérez10Nuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, MexicoNuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, MexicoNuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, MexicoNuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, MexicoNuclear Medicine Department, Universidad Autónoma de Bucaramanga, Bucaramanga 680002, ColombiaUrological Oncology Department, National Cancer Institute, Tlalpan, Mexico City 14080, MexicoUrological Oncology Department, National Cancer Institute, Tlalpan, Mexico City 14080, MexicoNuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, MexicoMedical Oncology Department, National Cancer Institute, Tlalpan, Mexico City 14080, MexicoMedical Oncology Department, National Cancer Institute, Tlalpan, Mexico City 14080, MexicoNuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, MexicoNeuroendocrine differentiation of prostate cancer (NEDPC) includes de novo presentation and secondary to epigenetic changes, referred as therapy-induced neuroendocrine prostate cancer (t-NEPC). Molecular imaging with prostate-specific membrane antigen (PSMA) and somatostatin analogues positron emission tomography (PET/CT) in NEDPC have not been validated. <sup>18</sup>F-FDG (fluorodeoxyglucose) PET/CT has numerous limitations in prostate cancer (PCa) and the utility in NEDPC has only been reported in a few series of cases. The objective of this study is to compare the lesions detection rate of the three radiotracers in metastatic t-NEPC patients. (1) Material and Methods: Retrospective evaluation of patients with prostate adenocarcinoma treated with androgen deprivation therapy, chemotherapy, a novel androgen receptor pathway inhibitor or a combination of them and a second tumour biopsy confirming t-NEPC was made. All patients underwent <sup>18</sup>F PSMA-1007, <sup>18</sup>F AlF-NOTA-Octreotide, and <sup>18</sup>F-FDG PET/CT. Evaluation of positive lesions was determined and SUVmax of each radiotracer was estimated and correlated with computer tomography (CT) findings. (2) Results: A total of eight patients were included. The mean time from diagnosis of prostate adenocarcinoma to t-NEPC was 28.2 months, with a mean serum specific prostate antigen (PSA) of 16.6 ng/dl at the time of NEPC diagnosis. All patients were treated with antiandrogen therapy and 87.5% with chemotherapy. A total of 273 lesions were identified by CT from which 182 were detected by <sup>18</sup>F-FDG PET/CT, 174 lesions by <sup>18</sup>F PSMA-1007, and 59 by <sup>18</sup>F AlF-NOTA-Octreotide. An interpatient analysis of the lesions was performed and dual tracer <sup>18</sup>F-FDG PET/CT and <sup>18</sup>F PSMA-1007 PET/CT detected a total of 270/273 lesions (98.9%). (3) Conclusions: NEDPC patients demonstrated wide inter and intrapatient molecular imaging heterogeneity within the three radiotracers. <sup>18</sup>F-FDG detected most lesions in t-NEPC among all radiotracers, especially in visceral sites; <sup>18</sup>F PSMA-1007 detected more bone lesions. <sup>18</sup>F AlF-NOTA-Octreotide showed no significant utility.https://www.mdpi.com/2075-4418/12/6/1387prostate cancerneuroendocrine differentiationPET/CTmolecular imaging |
| spellingShingle | Joel Vargas Ahumada Sofía D. González Rueda Fabio A. Sinisterra Solís Quetzali Pitalúa Cortés Liliana P. Torres Agredo Jimenez Ríos Miguel Anna Scavuzzo Irma Soldevilla-Gallardo Miguel A. Álvarez Avitia Nora Sobrevilla Francisco Osvaldo García Pérez Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation Diagnostics prostate cancer neuroendocrine differentiation PET/CT molecular imaging |
| title | Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation |
| title_full | Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation |
| title_fullStr | Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation |
| title_full_unstemmed | Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation |
| title_short | Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation |
| title_sort | multitarget molecular imaging in metastatic castration resistant adenocarcinoma prostate cancer with therapy induced neuroendocrine differentiation |
| topic | prostate cancer neuroendocrine differentiation PET/CT molecular imaging |
| url | https://www.mdpi.com/2075-4418/12/6/1387 |
| work_keys_str_mv | AT joelvargasahumada multitargetmolecularimaginginmetastaticcastrationresistantadenocarcinomaprostatecancerwiththerapyinducedneuroendocrinedifferentiation AT sofiadgonzalezrueda multitargetmolecularimaginginmetastaticcastrationresistantadenocarcinomaprostatecancerwiththerapyinducedneuroendocrinedifferentiation AT fabioasinisterrasolis multitargetmolecularimaginginmetastaticcastrationresistantadenocarcinomaprostatecancerwiththerapyinducedneuroendocrinedifferentiation AT quetzalipitaluacortes multitargetmolecularimaginginmetastaticcastrationresistantadenocarcinomaprostatecancerwiththerapyinducedneuroendocrinedifferentiation AT lilianaptorresagredo multitargetmolecularimaginginmetastaticcastrationresistantadenocarcinomaprostatecancerwiththerapyinducedneuroendocrinedifferentiation AT jimenezriosmiguel multitargetmolecularimaginginmetastaticcastrationresistantadenocarcinomaprostatecancerwiththerapyinducedneuroendocrinedifferentiation AT annascavuzzo multitargetmolecularimaginginmetastaticcastrationresistantadenocarcinomaprostatecancerwiththerapyinducedneuroendocrinedifferentiation AT irmasoldevillagallardo multitargetmolecularimaginginmetastaticcastrationresistantadenocarcinomaprostatecancerwiththerapyinducedneuroendocrinedifferentiation AT miguelaalvarezavitia multitargetmolecularimaginginmetastaticcastrationresistantadenocarcinomaprostatecancerwiththerapyinducedneuroendocrinedifferentiation AT norasobrevilla multitargetmolecularimaginginmetastaticcastrationresistantadenocarcinomaprostatecancerwiththerapyinducedneuroendocrinedifferentiation AT franciscoosvaldogarciaperez multitargetmolecularimaginginmetastaticcastrationresistantadenocarcinomaprostatecancerwiththerapyinducedneuroendocrinedifferentiation |